Singapore markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
84.50+3.11 (+3.82%)
At close: 04:00PM EST
84.54 +0.04 (+0.05%)
After hours: 07:58PM EST

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000

IndustryDrug Manufacturers—General
Full-time employees14,400

Key executives

NameTitlePayExercisedYear born
Mr. Daniel P. O'DayChairman & CEO6.09MN/A1964
Mr. Andrew D. DickinsonExec. VP & CFO2.55MN/A1970
Ms. Johanna MercierChief Commercial Officer2.92MN/A1970
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer2.68MN/A1963
Ms. Diane E. WilfongSr. VP, Corp. Controller & Chief Accounting OfficerN/AN/A1962
Ms. Jacquie Ross C.F.A.VP of Investor RelationsN/AN/AN/A
Ms. Deborah H. TelmanExec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.N/AN/A1965
Ms. Jyoti K. MehraExec. VP of HRN/AN/A1976
Dr. Michael Quigley Ph.D.Sr. VP of Research BiologyN/AN/AN/A
Dr. Linda Slanec Higgins Ph.D.Sr. VP & Head of External InnovationN/AN/A1962
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Corporate governance

Gilead Sciences, Inc.’s ISS governance QualityScore as of 1 February 2023 is 1. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 3; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.